Target identification and validation are key challenges in drug discovery. By applying Limited Proteolysis coupled with Mass Spectrometry (LiP-MS), our Drug Target Deconvolution service offers a unique way to help you optimize and de-risk your drug discovery journey.
Unveiling the target of a small molecule compound is key to gaining deeper insight into its mechanism of action and potential toxicities.
Limited Proteolysis Mass Spectrometry (LiP-MS) is a novel, label-free approach to identify on- and off-target binding effects throughout the proteome. LiP-MS is the only tool to probe protein structural alterations on a proteome scale with peptide-level resolution.
The study report will provide you with ranked protein target candidates for rapid target deconvolution and streamlined target validation.
Biognosys is the sole, exclusive provider of proteomics solutions based on the patented LiP-MS technology, developed in collaboration with the group of Prof. Paola Picotti at ETH Zurich.
“The LiP technology is a very valuable tool to identify target and off-target of novel compounds whatever the organism and to support the process of target deconvolution in research. The interactions with Biognosys are very nice and fruitful. The team is engaged and responsive throughout the project.”
Laboratory Manager, Bayer
The results are presented and discussed with you in a seminar or webinar and delivered electronically in PDF and Excel formats.
Dose response curves for LiP peptides from protein candidates
a) Protein target candidates ranked by aggregate LiP score
b) Compound affinity concentration for each protein candidate
c) Mapping of regulated peptides of top 3 candidates on protein tertiary structures if available
Drug Target Deconvolution is applicable to complex biological matrices, including a wide variety of cell lines and organisms.
Biognosys is committed to providing the best possible results to our customers at the fastest possible project turnaround time.
Learn more about Biognosys’ proprietary TrueTarget™ platform in our latest brochure. This resource elaborates on how TrueTarget™ identifies the most promising and actionable [...]
Target identification is a critical step in elucidating the mechanism of action (MoA) for bioactive compounds. For target-based and phenotypic drug discovery pipelines, extensive p [...]
Piazza I et al. Nature Communications. Chemoproteomics enables protein target identification of bioactive compounds, unraveling the mode of action of drug [...]